66th ASH Annual Meeting: 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II

Symposia: Health Services and Quality Improvement: Lymphoid Malignancies Oral and Poster Abstracts
Poster

Research, Viral, Hodgkin lymphoma, Fundamental Science, Adult, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Lymphomas, Non-Hodgkin lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, B Cell lymphoma, Drug-drug interactions, Clinical Research, Health outcomes research, Diversity, Equity, and Inclusion (DEI), T Cell lymphoma, Health disparities research, Education, Supportive Care, Diseases, Indolent lymphoma, Therapy sequence, Patient-reported outcomes, Treatment Considerations, Infectious Diseases, Biological therapies, Aggressive lymphoma, Real-world evidence, Adverse Events, Lymphoid Malignancies, Registries, Study Population, Human

Halls G-H (San Diego Convention Center)

3645

Virtual Care Use for Patients with Hematologic Malignancies – a Natural Policy Experiment

Adam Suleman, MD^1,2, Amy Zhihui Zhu, PhD³^*, Anna Sinaiko, PhD⁴^*, Anca Prica, MD, MSc²^* and Danielle Rodin, MD, MPH⁵^*

¹Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada
²Department of Medicine, University of Toronto, Toronto, ON, Canada
³University Health Network, Toronto, ON, Canada
⁴Department of Health Policy and Management, Harvard School of Public Health, Boston, MA
⁵Division of Radiation Oncology, Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada

3646

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

David Fox¹^*, Katherine L Rosettie¹^*, Fadoua El Moustaid¹^*, Anthony Masaquel¹^*, Lourenia Cassoli¹^* and Christopher R. Flowers, MD, MS²

¹Genentech, Inc., South San Francisco, CA
²MD Anderson Cancer Center, Houston, TX

3647

A Healthcare Utilization Model Comparing Time Toxicity between Glofitamab and Epcoritamab

Pallawi Torka, MD¹, Anthony Masaquel²^*, Lourenia Cassoli²^*, David Fox²^*, Arliene Ravelo²^* and Ajay Major, MD, MBA³

¹Memorial Sloan Kettering, New York, NY
²Genentech, Inc., South San Francisco, CA
³University of Colorado School of Medicine, Aurora, CO

3648

Mosunetuzumab is Cost-Effective Compared with Alternative Novel Treatment Options in Patients with Third-Line or Later Relapsed/Refractory Follicular Lymphoma Over a Long-Term Horizon in the United States

Matthew Matasar, MD, MS¹, Katherine L Rosettie²^*, Almut Mecke³^*, Danilo Di Maio³^*, Shih-Wen Lin²^*, Mei Wu²^* and Esprit Ma²^*

¹Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ
²Genentech, Inc., South San Francisco, CA
³F. Hoffmann-La Roche Ltd, Basel, Switzerland

3649

Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001

Kristine A Karvonen, MD^1,2, Morgan A. Paul, MS³^*, Yael Flamand, MS³^*, Puja J. Umaretiya, MD⁴^*, Rahela Aziz-Bose, MD^5,6,7, Colleen A. Kelly, MD^5,6, Leanne Duhaney, MD, MPH⁸^*, Daniel J. Zheng, MD⁹, Lucille Lokko, BA⁵^*, Victoria Koch, BS¹⁰^*, Peter D. Cole, MD¹¹, Lisa M. Gennarini, MD¹²^*, Justine M. Kahn, MD, MSc¹³, Kara M. Kelly, MD^14,15, Thai Hoa Tran, MD¹⁶, Bruno Michon, MD¹⁷^*, Jennifer J.G. Welch, MD¹⁸, Joanne Wolfe, MD, MPH¹⁹^*, Lewis B. Silverman, MD²⁰ and Kira Bona, MD, MPH^5,6,21

¹Seattle Children's Research Institute, Seattle, WA
²Department of Pediatric Hematology/Oncology, University of Washington, SEATTLE, WA
³Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁴Childrens Medical Center Dallas, UT Southwestern, Dallas, TX
⁵Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA
⁷Division of Population Sciences, Dana-Farber Cancer Institute, Jamaica Plain, MA
⁸Department of Cardiology, Boston Children's Hospital, Boston, MA
⁹Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA
¹⁰Dana-Farber Cancer Institute, Boston, MA
¹¹Division of Pediatric Hematology/Oncology, Rutgers Cancer Institute, New Brunswick, NJ
¹²Division of Pediatric Hematology/Oncology and Blood & Marrow Cell Transplant, Montefiore Medical Center, Bronx, NY
¹³Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Columbia University Irving Medical Center, New York, NY
¹⁴Roswell Park Cancer Center, Buffalo, NY
¹⁵Division of Pediatric Hematology/Oncology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY
¹⁶Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Montreal, QC, Canada
¹⁷Centre Hospitalier de l'Universite Laval, Quebec City, QC, Canada
¹⁸Division of Pediatric Hematology and Oncology, Hasbro Children’s Hospital, Warren Alpert Medical School of Brown University, Providence, RI
¹⁹Departments of Pediatrics, Massachusetts General and Brigham and Women’s Hospitals, Boston, MA
²⁰Division of Pediatric Hematology/Oncology, Columbia University Irving Medical Center, New York, NY
²¹Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA

3650

Meeting Cancer Survivorship Needs in Hematological Malignancies Compared to Solid Malignancies: Experiences of a Primary Care-Based Survivorship Clinic

Ellen Zhang, MD, Natasha Steele, MD, MPH^*, Maya Ramachandran, MD^* and Ilana Yurkiewicz, MD

Stanford Health Care, Palo Alto, CA

3651

Cost Consequence and Time Toxicity Model for the Treatment of Third-Line or Later (3L+) Follicular Lymphoma (FL) Using Advanced Therapies: A Comparison of Lisocabtagene Maraleucel (liso-cel) with Mosunetuzumab

Saurabh Dahiya, MD, FACP¹^*, Ashley C. Saunders, MPH, MSc²^*, Jinender Kumar, MS²^*, William Ngantung, BS³^* and Matia Saeedian, PharmD, MS³^*

¹Stanford University School of Medicine, Stanford, CA
²Bristol Myers Squibb, Princeton, NJ
³BluePath Solutions, Los Angeles, CA

3652

Comparison of Healthcare Utilization in Patients Undergoing CAR T-Cell Therapy for Multiple Myeloma and Lymphoma

Kim Abbegail Tan Aldecoa, MD^1,2, Kah Poh Loh, MD, MBBCH BAO, MS³, Yi Lee, MD⁴^*, Noha Soror, MD, MSc⁵, Camelia Arsene, MD, PhD, MHS^1,2^*, Geetha Krishnamoorthy, MD^1,2^* and Meera Mohan, MD⁶

¹Department of Internal Medicine, Trinity Health Oakland, Pontiac, MI
²Wayne State University, Detroit, MI
³University of Rochester Medical Center, Rochester, NY
⁴Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
⁵Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma, OK
⁶Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

3653

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Michael Slade, MD, MS¹, Ravi Vij, MD, MBA¹, Keith Stockerl-Goldstein, MD², Mark A. Schroeder, MD², Angela Vickroy, ANP²^*, Margaret Kavanaugh, ANP-BC¹^*, Carmen Wilson, PA-C¹^* and Mark Fiala, PhD¹^*

¹Division of Oncology, Washington University School of Medicine, Saint Louis, MO
²Division of Oncology, Washington University School of Medicine, St. Louis, MO

3654

Changes in Treatment Patterns over Time Among Real-World Patients with Follicular Lymphoma at Predominantly Community Facilities in the US

Swetha Kambhampati Thiruvengadam, MD¹, Allison Dillon²^*, Paul Cockrum³^* and Syvart Dennen⁴^*

¹City of Hope National Medical Center, Yorba Linda, CA
²Genesis Research, Hoboken, NJ
³Ipsen Biopharmaceuticals, Inc., Cambridge, MA
⁴Genesis Research Group, Hoboken, NJ

3655

Patient Medication Preferences in Follicular Lymphoma (FL) in the United States (USA): A Discrete-Choice Experiment (DCE)

Sameh Gaballa, MD¹, Mei Xue²^*, Todor I Totev, MBA³^*, Yan Meng, PhD⁴^*, Swetha Challagulla²^*, Zhuo Chen³^* and Keri Yang²^*

¹Moffitt Cancer Center, Tampa, FL
²BeiGene, San Mateo, CA
³Analysis Group, Inc., Boston, MA
⁴Analysis Group, Ltd, London, United Kingdom

3656

Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party

Gloria Iacoboni, MD¹^*, Pere Barba, MD¹, Irma Khvedelidze²^*, Maud Ngoya²^*, Paolo Corradini, MD³, Pierre Sesques, MD⁴^*, Marion Subklewe, MD⁵, Maria Gomes Da Silva⁶^*, Gilles Crochet⁷^*, Jarosław Dybko⁸^*, Izaskun Zeberio⁹^*, Alejandro Martín García-Sancho¹⁰^*, Tom van Meerten¹¹^*, Maeve O'Reilly¹²^*, Bertram Glass, MD¹³^*, Ana Maria Sureda Balari, MD, PhD¹⁴, Peter Dreger¹⁵, Olivier Hermine, MD, PhD¹⁶^* and Ali Bazarbachi, MD, PhD¹⁷

¹University Hospital Vall d’Hebron, Barcelona, Spain
²EBMT Paris Study Unit, Paris, France
³Fondazione IRCCS Istituto Nazionale dei Tumori Milano, University of Milano, Milano, Italy
⁴CHU Lyon-Sud, Lyon, France
⁵Department of Medicine III, LMU University Hospital, Munich, Germany
⁶Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, PRT
⁷CHU UCL Namur, Yvoir, Belgium
⁸Department of Hematology and Cellular Transplantation, Lower Silesian Oncology Center, Wroclaw, Poland
⁹Hematology Department, Hospital Universitario Donostia, San Sebastian, ESP
¹⁰Hospital Universitario de Salamanca, IBSAL, CIBERONC, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain
¹¹Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
¹²Department of Hematology, University College London Hospitals, London, United Kingdom
¹³Department of Hematology and Stem Cell Transplantation, Helios Klinikum Berlin-Buch, Berlin, Germany
¹⁴Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
¹⁵Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
¹⁶INSERM U1163 Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, Institut IMAGINE, Université Paris Cité, Paris, France
¹⁷American University of Beirut Dept. of Medicine, Beirut, Lebanon

3657

Using Circulating Tumor DNA to Spare Patients with DLBCL Unnecessary Treatment and Cost: A Model-Based Analysis

Edward R Scheffer Cliff, MBBS, MPH^1,2, David A Russler-Germain, MD, PhD³ and Amar H. Kelkar, MD, MPH, FACP^4,5

¹Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
²Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia
³Siteman Cancer Center, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
⁴Department of Medicine, Division of Hematology & Oncology, Harvard Medical School, Boston, MA
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

3658

Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies across Diverse Clinical Landscapes: An International Prospective Study

Sikander Ailawadhi¹, Yelak Biru²^*, Solène Clavreul³^*, Maite San Miguel⁴^*, Nicolas Cormier⁵^*, Anna Sato⁶^*, Cathy Zeanah⁶^*, James Farrell⁷^*, Erinn Hoag Goldman⁸ and Rakesh Popat⁹^*

¹Division of Hematology-Oncology, Mayo Clinic-Florida, Jacksonville, FL
²International Myeloma Foundation, Greater Los Angeles, CA
³Myeloma Patients Europe, Brussels, Belgium
⁴Clínica Universidad de Navarra, Pamplona, Spain
⁵Centre Hospitalier Universitaire de Nantes, NANTES, FRA
⁶ZS Associates, New York, NY
⁷Pfizer Ltd, Dublin, Ireland
⁸Pfizer Inc, New York, NY
⁹National Institute for Health Research Clinical Research Facility, University College London Hospitals NHS Trust, London, GBR

3659

Global Access to Chimeric Antigen Receptor (CAR) T-Cell Therapies: Health Technology Assessment (HTA) of CAR T in G7 Countries and Australia

Alex Y Ge, MD¹^*, William B Feldman, MD, DPhil, MPH^2,3^*, Martin F Kaiser, MD⁴, Kai Rejeski, MD^5,6, Gloria Iacoboni, MD⁷^*, Michael J Dickinson, MBBS, DMedSci, FRACP, FRCPA^8,9, Aaron S Kesselheim, MD, JD, MPH³^* and Edward R Scheffer Cliff, MBBS, MPH^8,10,11

¹Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA
²Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
³Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
⁴The Institute of Cancer Research, London, ENG, United Kingdom
⁵Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany
⁷Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Universitat Autònoma of Barcelona (UAB), Barcelona, Spain
⁸Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
⁹Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
¹⁰Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
¹¹Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia

3660

Outcomes of Elderly Patients with DLBCL and Utility of Geriatric Assessment Tools to Predict Chemotoxicity

Xinjie Jonathan Tang, MBBS¹, Joanne Shu Xian Lee²^*, Esther Hian Li Chan^1,3^*, Sanjay De Mel, BSc, FRCPath, MRCP⁴^*, Yen-Lin Chee^2,3^*, Wee-Joo Chng^3,4,5, Nicole-Ann Lim⁶^*, Jason Yongsheng Chan⁶, Soon Thye Lim⁶^*, Shi Hui Clarice Choong^1,3^*, Melissa Gaik-Ming Ooi^1,3^* and Michelle Limei Poon^1,3^*

¹Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore
²Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
³Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
⁴Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Health System, Singapore, Singapore
⁵Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
⁶Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore

3661

Associations of Long-Term Financial Hardship with Autologous Transplant and Overall Survival in Patients with Multiple Myeloma

Christopher T. Su, MD, MPH^1,2, Rahul Banerjee, MD, FACP^1,3, Li Li, MA MPA¹^*, Catherine Fedorenko, MMSc¹^*, Andrew J. Cowan, MD^1,2, Scott D. Ramsey, MD PhD^1,2^* and Veena Shankaran, MD MS^1,2^*

¹Fred Hutchinson Cancer Center, Seattle, WA
²University of Washington, Seattle, WA
³University of Washington Fred Hutchinson Cancer Center, Seattle, WA

3662

Systems-Based Care Improvements to Optimize BTK Inhibitors in Chronic Lymphocytic Leukemia Vary in the Community Setting

Tariqa Ackbarali, MSc¹^*, Danielle M. Brander, MD² and Matthew S. Davids, MD, MMSc³

¹PlatformQ Health, Lake Worth, FL
²Duke University, Durham, NC
³Department of Medical Oncology, Dana-Farber Cancer Institute, Inc., Boston, MA

3663

Impact of Patient Distance from Center on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Brian Hoeynck, MD¹, Shakthi Bhaskar, MD², Andrew P Jallouk, MD, PhD³, Bhagirathbhai R. Dholaria, MBBS¹, Bipin N. Savani, MD², Olalekan O. Oluwole, MD, MPH, MBBS², David Morgan, MD²^*, Salyka M. Sengsayadeth, MD²^*, Adetola A. Kassim, MBBS, MS¹ and Vivek Patel, MD²

¹Vanderbilt University Medical Center, Nashville, TN
²Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
³The University of Texas MD Anderson Cancer Center, Nashville, TN

3664

Remote Patient Monitoring for Early Detection of Cytokine Release Syndrome in Myeloma Patients: A Comparative Study between Standard Care and Remote Monitoring

Anneleen Vanhellemont, MSc, RN¹^*, Annemarie Coolbrandt, MSc, RN¹^*, Evi Vandeneede, MSc, RN¹^*, Gwen Aerts, MSc²^*, Lise Lynen, MSc²^*, Yoline Soeffers, MSc³^*, Annouschka Laenen, MSc⁴^*, Peter Vandenberghe, MD, PhD^5,6 and Michel Delforge^5,7^*

¹Leuven, University Hospital, Leuven, Belgium
²Byteflies, Antwerpen, Belgium
³University Leuven, Leuven, Belgium
⁴Leuven Biostatistics and Bio informatics Centre, University Leuven, Leuven, Belgium
⁵University Hospital Gasthuisberg, Leuven, Belgium
⁶Department of Hematology, Department of Human Genetics, University Hospitals Leuven, KU Leuven, Leuven, Belgium
⁷University Hospital Leuven, Leuven, Belgium

3665

A Medical Chart Review of Healthcare Costs in Patients with Systemic Amyloid Light Chain Amyloidosis By Mayo 2012 Stage in the United States

Morie A. Gertz, MD¹, Heather J. Landau, MD², Vaishali Sanchorawala³, Manisha Bhutani, MD⁴, Jeffrey A. Zonder, MD ⁵, Michael Rosenzweig, MD⁶, Gray Magee, MD⁷, Cynthia Campos, MPH⁸^*, Irina Yermilov, MD, MPH, MS⁸^*, Eunice Chang, PhD⁸^*, Michael S. Broder, MD, MSHS⁸^* and Preeti Bajaj, PhD⁹^*

¹Division of Hematology, Mayo Clinic, Rochester, MN
²Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
³Section of Hematology and Medical Oncology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA
⁴Atrium Health Levin Cancer Institute, Charlotte, NC
⁵Karmanos Cancer Institute, Detroit, MI
⁶Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA
⁷Levine Cancer, Atrium Health, Charlotte, NC
⁸PHAR (Partnership for Health Analytic Research), Beverly Hills, CA
⁹Prothena Biosciences, Inc., South San Francisco, CA

3666

Real-World Treatment Patterns, Healthcare Resource Use, and Costs Among Patients with Waldenstrӧm Macroglobulinemia: A Retrospective Analysis of US Claims Data

Mahek Garg, PhD¹, Ambika Satija, PhD²^*, Yan Song, PhD²^*, Ben Meade, BA³^*, James Signorovitch, PhD²^* and Shravanthi Gandra, PhD, MBA⁴^*

¹Merck Sharp & Dohme LLC, Rahway, NJ
²Analysis Group, Inc., Boston, MA
³Analysis Group, Inc, Paris, France
⁴Merck & Co., Inc., Rahway, NJ

3667

Impact of Health Literacy in Hematology Outpatients Receiving Oral Anticancer Drugs and Followed By the Oncoral Multidisciplinary City-Hospital Educational Follow-up

Chloé Herledan, PhD, PharmD^1,2^*, Florence Ranchon, PharmD, PhD^2,3^*, Marie Preau, PhD⁴^*, Agathe Komaroff⁵^*, Anissa Guillemin, PhD^2,5^*, Magali Maire, PhD⁶^*, Anne-Gaëlle Ruiz-Caffin, PharmD⁷^*, Lionel Karlin⁸^*, Emmanuelle Ferrant⁹^*, Gilles Salles, MD, PhD¹⁰, Hervé Ghesquieres, MD, PhD¹¹^* and Catherine Rioufol, PharmD, PhD³^*

¹Pharmacy Department, Lyon Sud University Hospital, Pierre-Benite, CZ, France
²EA 3738 CICLY, Lyon 1 University, Oullins, France
³Pharmacy Department, Lyon Sud University Hospital, Pierre-Benite, France
⁴UMR 1296 Radiations : Défense, Santé, Environnement, Lyon 2 University, Lyon, France
⁵Lyon Sud University Hospital, Pierre-Bénite, France
⁶Hematology Department, Lyon Sud University Hospital, Pierre-Benite, France
⁷Lyon Sud University Hospital, Pierre-Benite, France
⁸Department of Hematology, Hospices Civils de Lyon, Lyon Sud University Hospital, Pierre-Bénite, France
⁹Department of Hematology, Lyon Sud Hospital, Pierre Benite, France
¹⁰Lymphoma Service Chief, Memorial Sloan Kettering Cancer Center, New York, NY
¹¹Department of Hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France

3668

Autologous Stem Cell Transplant for HIV-Associated Lymphoma: A Systematic Review and Meta-Analysis

Maria Comelles, MD¹^*, Alexandra Grudzinski²^* and Lisa K Hicks, MD^3,4,5

¹St. Michael's Hospital, University of Toronto, Toronto, Argentina
²Division of Hematology/Oncology, St. Michael’s Hospital, Toronto, ON, Canada
³Li Ka Shing Knowledge Institute, University of Toronto, Toronto, ON, Canada
⁴Division of Hematology/Oncology, St. Michael's Hospital, Toronto, ON, Canada
⁵Department of Medicine, University of Toronto, Toronto, ON, Canada

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH